Asia Pacific Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Size & Outlook
Related Markets
Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market highlights
- The Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market generated a revenue of USD 38.4 million in 2025.
- The market is expected to grow at a CAGR of 16.9% from 2026 to 2033.
- In terms of segment, tau-related markers was the largest revenue generating type in 2025.
- Amyloid-related markers is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 38.4 million |
| Market revenue in 2033 | USD 134.1 million |
| Growth rate | 16.9% (CAGR from 2026 to 2033) |
| Largest segment | Tau-related markers |
| Fastest growing segment | Amyloid-related markers |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Amyloid-related markers, Tau-related markers, Neurodegeneration, Others Type |
| Key market players worldwide | F. Hoffmann-La Roche AG, Quanterix, Fujirebio Diagnostics, C2N Diagnostics, Labcorp Holdings Inc, Quest Diagnostics Inc, Siemens Healthineers AG ADR, Eli Lilly and Co, Abbott Laboratories |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.7% of the global blood-based biomarker for alzheimer’s disease diagnostics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 134.1 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Scope
Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Quanterix | View profile | 251-500 | Billerica, Massachusetts, United States, North America | http://www.quanterix.com |
| Fujirebio Diagnostics | View profile | 5001-10000 | Malvern, Pennsylvania, United States, North America | http://www.fdi.com/ |
| C2N Diagnostics | View profile | 11-50 | Saint Louis, Missouri, United States, North America | https://c2n.com/ |
| F. Hoffmann-La Roche AG | View profile | - | - | - |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
| Labcorp Holdings Inc | View profile | 67000 | 358 South Main Street, Burlington, NC, United States, 27215 | https://www.labcorp.com |
| Quest Diagnostics Inc | View profile | 48000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | https://www.questdiagnostics.com |
| Siemens Healthineers AG ADR | View profile | 71400 | Siemensstr. 3, Forchheim, BY, Germany, 91301 | https://www.siemens-healthineers.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood-based biomarker for alzheimer’s disease diagnostics market will help companies and investors design strategic landscapes.
Tau-related markers was the largest segment with a revenue share of 53.13% in 2025. Horizon Databook has segmented the Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market based on amyloid-related markers, tau-related markers, neurodegeneration, others type covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market databook
-
Our clientele includes a mix of blood-based biomarker for alzheimer’s disease diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific blood-based biomarker for alzheimer’s disease diagnostics market size, by country, 2021-2033 (US$M)
Asia Pacific Blood-based Biomarker For Alzheimer’s Disease Diagnostics Market Outlook Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
